- Home
- ASC vs GLUE Comparison
ASC vs GLUE Comparison
Compare ASC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- GLUE
- Stock Information
- Founded
- ASC 2010
- GLUE 2019
- Country
- ASC Bermuda
- GLUE United States
- Employees
- ASC N/A
- GLUE N/A
- Industry
- ASC Marine Transportation
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- GLUE Health Care
- Exchange
- ASC Nasdaq
- GLUE Nasdaq
- Market Cap
- ASC 399.7M
- GLUE 351.2M
- IPO Year
- ASC 2013
- GLUE 2021
- Fundamental
- Price
- ASC $10.65
- GLUE $4.58
- Analyst Decision
- ASC Buy
- GLUE Buy
- Analyst Count
- ASC 3
- GLUE 2
- Target Price
- ASC $12.67
- GLUE $13.50
- AVG Volume (30 Days)
- ASC 603.2K
- GLUE 424.6K
- Earning Date
- ASC 07-30-2025
- GLUE 08-07-2025
- Dividend Yield
- ASC 8.92%
- GLUE N/A
- EPS Growth
- ASC N/A
- GLUE N/A
- EPS
- ASC 1.04
- GLUE 0.29
- Revenue
- ASC $324,200,000.00
- GLUE $177,986,000.00
- Revenue This Year
- ASC N/A
- GLUE $49.02
- Revenue Next Year
- ASC N/A
- GLUE N/A
- P/E Ratio
- ASC $10.11
- GLUE $15.82
- Revenue Growth
- ASC N/A
- GLUE 2990.57
- 52 Week Low
- ASC $8.32
- GLUE $3.50
- 52 Week High
- ASC $20.17
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- ASC 53.93
- GLUE 44.59
- Support Level
- ASC $10.17
- GLUE $4.30
- Resistance Level
- ASC $10.65
- GLUE $4.66
- Average True Range (ATR)
- ASC 0.43
- GLUE 0.31
- MACD
- ASC -0.04
- GLUE -0.07
- Stochastic Oscillator
- ASC 39.67
- GLUE 30.28
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.